Exciting Developments from ALX Oncology
ALX Oncology Holdings Inc., a pioneering clinical-stage biotechnology company, has some promising news to share. Focused on revolutionizing cancer treatment through immune system enhancement, the company has announced significant findings from its Phase 1b/2 trial. This study evaluates evorpacept, ALX’s lead therapeutic candidate, in combination with zanidatamab.
Details of the Clinical Trial
The trial targets patients with HER2-positive and HER2-low metastatic breast cancer. This dual-part, open-label multicenter study aims to assess the effectiveness of evorpacept paired with zanidatamab as a novel treatment option. Acceptance for spotlight presentation at the San Antonio Breast Cancer Symposium (SABCS) confirms the relevance and importance of the results involved in this clinical exploration.
Presentation Highlights
The captivating insights from this study will be shared in a poster spotlight presentation at SABCS, occurring in December. Notable details for this presentation include its title: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study. Alberto J. Montero, M.D., will serve as the presenter, delivering insights into how these therapies may reshape treatment landscapes.
ALX Oncology's Mission and Vision
As a company, ALX Oncology is committed to building innovative therapies aimed at harnessing the body’s immune response against cancer. Their focus on evorpacept exemplifies this mission, showing potential not just as an isolated therapy but as a foundational pillar in immuno-oncology.
Ongoing Trials and Future Directions
Currently, evorpacept is being examined in various clinical trials, addressing multiple types of cancer. This ongoing research signifies ALX Oncology’s commitment toward providing safer and more effective treatment alternatives for cancer patients. With future evaluations anticipated, the landscape of cancer treatment may soon undergo dramatic shifts thanks to these efforts.
Company Commitment to Patients and Community
ALX Oncology does not merely focus on novel therapies; they prioritize patient engagement and community support. As they continue to navigate the complexities of cancer treatment, their dedication to transparency and patient-centric approaches is invaluable.
Contact Information for Inquiries
For those interested in more details about ALX Oncology's developments, the company’s communications team is ready to assist. Caitlyn Doherty can be reached for corporate communications inquiries, while investor relations inquiries can be directed to Malini Chatterjee. The media contact for any press-related queries is Audra Friis.
Frequently Asked Questions
What is the focus of the Phase 1b/2 trial?
The trial evaluates evorpacept in combination with zanidatamab for HER2-positive and HER2-low metastatic breast cancer.
Who is presenting the results of the study?
Alberto J. Montero, M.D., will present the results during the spotlight session at the SABCS.
When and where will the presentation take place?
The presentation will occur on Thursday, December 12, at the Henry B. Gonzalez Convention Center in San Antonio.
What is the potential impact of evorpacept?
Evorpacept aims to provide a new cornerstone therapy in immuno-oncology, enhancing the immune system's ability to fight cancer.
How can I learn more about ALX Oncology's initiatives?
Interested individuals can visit the company's official website or reach out directly to their communication or investor relations teams.
